Philippines FDA approves first ever generic version of Pfizer anti-Covid pill

Manila (Philippines), January 25: The Philippines Food and Drug Administration (FDA) has approved the world’s first generic version of Pfizer’s anti-Coronavirus pill Paxlovid, just days after the original was granted Emergency Use Authorisation (EUA) by the US FDA.

The Philippines FDA has approved the department of health’s application for a compassionate special permit application for the first generic version of Paxlovid that has been launched by Beximco Pharmaceuticals, a leading generic drugmaker from Bangladesh.

Philippines-based Pharmaceutical company Biocare Lifesciences Inc would be the distributor and importer of a generic drug, which would be sold under the brand name Bexovid in the Philippines.

According to Pfizer, the risk of hospitalisation or death is reduced by 89% when Paxlovid is given within three days of the onset of symptoms and by 88% when given within five days of the onset of symptoms. The treatment, a combination of Nirmatrelvir and Ritonavir tablets, is given together twice a day for five days and is recommended for treatment of mild to moderate cases of Covid-19.

Pfizer data also suggests the drug remains effective against the faster-spreading Omicron variant of the Coronavirus, which is driving the latest surge in Covid-19 cases globally.

“The approval by the Philippines FDA will make Bexovid accessible to Covid-19 patients in the country and add another treatment protocol to the existing drugs. We plan to import 20,000 to 30,000 courses of Bexovid initially and expect the supplies to begin in the first week of February. Bexovid is expected to be priced 50-60% cheaper than the original Pfizer drug, making it an affordable option,” said Dileep Tiwari, Managing Director, Biocare Lifesciences, during an interview with CNN.

Bexovid is recommended as an at-home treatment to help reduce the severity of the infection. The drug has the potential to eliminate many hospitalizations, thus helping reduce the strain on the healthcare infrastructure.

“Bexovid is not meant for patients who are hospitalised. Any patient who is Covid-19 positive can buy the drug from hospitals once supplies begin,” said Mr. Tiwari in a CNN interview.

Separately, Bangladesh’s Directorate General of Drug Administration has also granted EUA for Bexovid to treat mild-to-moderate Covid-19 cases in patients aged 12 and above.

Comments are closed.

Lifestyle Press Release

Joyneel Mukerji Pays Tribute To His Late Grandfather Shree Joy Mukerji

Mumbai (Maharashtra) [India], February 25: A deeply emotional musical tribute is set to celebrate the legacy of legendary Bollywood star Joy Mukerji as his grandson Joyneel Mukerji lends his voice to a soulful rendition of the Hanuman Chalisa, being released on Monjoy Mukerji’s MJM Records on Joy Mukerji’s 87th birth anniversary on 24 th February, 2026. The […]

Read More
Business Press Release

YAAP DIGITAL LIMITED IPO Opens on Feb 25, 2026

Mumbai (Maharashtra) [India], February 23: Yaap operates as a digital marketing, content, and technology services company within the fast-growing marketing and advertising landscape. The company is opening its Initial Public Offering on Feb 25, 2026, aiming to raise ₹ 80.11 Crores with shares to be listed on the NSE Emerge platform. The issue size is 55,25,000 equity […]

Read More
Business Press Release

Post Turnaround Medikabazaar Aims to Raise USD 50 Million to Fuel the Ambition of Billion-Dollar Company

New Delhi [India], February 20: In a sector where rapid scale has often come at the expense of sustainability, Medikabazaar’s recent turnaround marks a notable shift towards profitability and disciplined growth. Following a period of operational reset and under the leadership of its Group CEO Dinesh Lodha, the company has articulated a credible ambition: to […]

Read More